515 results on '"Mannelli Francesco"'
Search Results
2. Mastocytosis and the Bone: Observational Study
3. Underlying systemic mastocytosis in patients with unexplained osteoporosis: score proposal
4. Oral ondansetron versus domperidone for symptomatic treatment of vomiting during acute gastroenteritis in children: multicentre randomized controlled trial
5. Disease correlates and clinical relevance of hereditary α-tryptasemia in patients with systemic mastocytosis
6. Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia
7. Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
8. Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis
9. Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: A nationwide multicenter retrospective analysis
10. Catching the clinical and biological diversity for an appropriate therapeutic approach in systemic mastocytosis
11. Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial
12. Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature
13. JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis
14. Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2
15. Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models
16. The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation‐enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis
17. A globally applicable “triple A” risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count
18. ALL-256 Nelarabine, Etoposide, and Cyclophosphamide for Adult T Cell Acute Lymphoblastic Leukemia/lymphoma Relapsing After Pediatric-Inspired Frontline Approaches: Report of 3 Cases From a Real-Life Setting
19. POSTER: ALL-256 Nelarabine, Etoposide, and Cyclophosphamide for Adult T Cell Acute Lymphoblastic Leukemia/Lymphoma Relapsing After Pediatric-Inspired Frontline Approaches: Report of 3 Cases From a Real-Life Setting
20. AML-251 APL-Like Subset Within NPM1-Mutated Acute Myeloid Leukemia: A Distinct Phenotypic Signature Correlating With Early-Onset Vascular Complications
21. POSTER: AML-251 APL-Like Subset Within NPM1-Mutated Acute Myeloid Leukemia: A Distinct Phenotypic Signature Correlating With Early-Onset Vascular Complications
22. AML-284 Venetoclax in Combination With Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory NPM1-Mutated Acute Myeloid Leukemia: Clinical Experience From a Real-Life Setting
23. POSTER: AML-284 Venetoclax in Combination With Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory NPM1-Mutated Acute Myeloid Leukemia: Clinical Experience From a Real-Life Setting
24. P529: THE EFFECT OF AGE AND TREATMENT ON THE PREDICTIVE VALUE OF MEASURABLE RESIDUAL DISEASE: IMPLICATIONS FOR THE CLINICAL MANAGEMENT OF ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA
25. Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis
26. Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
27. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis
28. Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts
29. The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions
30. Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome
31. Validation of the Mayo alliance prognostic system for mastocytosis
32. Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study
33. Successful rechallenge with Erwinia chrysanthemi asparaginase after pegaspargase-induced hypertriglyceridemia: a case report.
34. The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation‐enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis.
35. Concomitant myeloproliferative neoplasm with eosinophilia, B and T cell lymphoblastic lymphoma/leukemia and mast cell proliferation driven by ZMYM2::FGFR1 rearrangement.
36. Multilineage dysplasia as assessed by immunophenotype has no impact on clinical-biological features and outcome of NPM1-mutated acute myeloid leukemia
37. Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real‐life setting: An Italian MYNERVA Project
38. ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms
39. The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis
40. Diagnostic and therapeutic challenges in mast cell sarcoma
41. JAK2V617F Molecular Response to Ruxolitinib in Patients with PV and ET Is Associated with Lower Risk of Progression to Secondary Myelofibrosis
42. Long Term Follow-up of an Investigator-Initiated Phase 2 Study of Ruxolitinib in MPN-Associated Splancnic Vein Thrombosis (SVT-RUXO)
43. Clinical, Molecular, and Histopathological Correlates in a Series of 24 Consecutive Cases of Suspected Myeloproliferative Neoplasms with a JAK2V617F Variant Allele Frequency ≤1%
44. Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis
45. Real-World Management of Advanced Systemic Mastocytosis Treated with Midostaurin: Analysis of Patients Who Completed 12 Months of Follow-up from an Italian Observational Study (OVIDIO)
46. Venetoclax in Combination with Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Single-Centre Experience
47. Vaccine effectiveness against severe laboratory-confirmed influenza in children: Results of two consecutive seasons in Italy
48. Clonal dynamics and copy number variants by single‐cell analysis in leukemic evolution of myeloproliferative neoplasms.
49. Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
50. Histopathology and Molecular Genetics in Systemic Mastocytosis: Implications for Clinical Management
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.